Resolution Pharmacology – new therapeutic approaches for the treatment of inflammatory diseases
-
Chair(s):
Patrícia Silva,
Researcher in Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, BrazilMauro Perretti,
Professor, Queen Mary University of London, London, United Kingdom -
Session description:
Development of FPR2 small molecules to treat heart failure: from preclinical to phase I trial
Dr Ricardo Garcia
Sr. Principal Scientist, Bristol-Myers Squibb Co., Princeton, NJ, The United States of AmericaAdvances in antifibrotic therapies for chronic lung diseases
Dr Patrícia Silva
Senior Researcher in Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, BrazilOral communication speaker - to be confirmed in 2023.
The Annexin A1 mimetic RTP-026 regulates the immune response to elicit protection in myocardial infarction
Dr Mauro Perretti
Professor, Queen Mary University of London, United KingdomAP1189: a biased agonist for melanocortin receptors in Phase IIa
Professor Thomas Jonassen
Syn Act Pharma, Holt, Denmark
Speakers
-
Dr Mauro PerrettiProfessor, Queen Mary University of London, United Kingdom
-
Dr Patrícia SilvaSenior Researcher in Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
-
Dr Ricardo GarciaSr. Principal Scientist, Bristol-Myers Squibb Co., Princeton, NJ, The United States of America
-
Professor Thomas JonassenSyn Act Pharma, Holt, Denmark